ICGEB-Emory Vaccine Program


Research Interests

Human immunology of infectious diseases, vaccine research and therapeutics.

Description of Research

The ICGEB-Emory Vaccine program, is a unique partnership between ICGEB and Emory Vaccine Center, Emory University (Atlanta, GA, USA).  The goal of this partnership is to facilitate international collaborations in vaccine research for tackling infectious diseases of public health importance in developing countries.

This partnership provides an opportunity for students, fellows, scientists and clinicians in India, to collaborate with international experts in human immunology of infectious diseases and vaccine research in order to address complex biological questions that are pertinent to infectious diseases of public health importance in India.

With support from NIH, DBT and Indo-US Vaccine Action Program, our present focus is to understand human immunity to infectious diseases, with particular emphasis on Dengue and Chikungunya virus infections in India. We will use this knowledge for identifying novel biomarkers, therapeutics and for improving vaccine design, testing and evaluation.

The Group, while continuing to study human immunity to the dengue and chikungunya viruses, has recently contributed extensively to understanding B cell responses to SARS-CoV-2 in recovered individuals from India (Nayak K, Virology in press). The lab has also been successful in making human monoclonal antibodies specific to the receptor binding protein of SARS-CoV-2 which can be explored for improved diagnostics, as well as for therapeutic and prophylatic regimes in the future.

Relevant links to Emory:

Recent Publications

Chandele, A., Sewatanon, J., Gunisetty, S., Singla, M., Onlamoon, N., Akondy, R.S., Kissick, H.T., Nayak, K., Reddy, E.S., Kalam, H., Kumar, D., Verma, A., Panda, H., Wang, S., Angkasekwinai, N., Pattanapanyasat, K., Chokephaibulkit, K., Medigeshi, G.R., Lodha, R., Kabra, S., Ahmed, R., Murali-Krishna, K. 2016. Characterization of Human CD8 T Cell Responses in Dengue Virus-Infected Patients from India. J Virol 90, 11259-11278 PubMed link

Carpenter, C., Sidney, J., Kolla, R., Nayak, K., Tomiyama, H., Tomiyama, C., Padilla, O.A., Rozot, V., Ahamed, S.F., Ponte, C., Rolla, V., Antas, P.R., Chandele, A., Kenneth, J., Laxmi, S., Makgotlho, E., Vanini, V., Ippolito, G., Kazanova, A.S., Panteleev, A.V., Hanekom, W., Mayanja-Kizza, H., Lewinsohn, D., Saito, M., McElrath, M.J., Boom, W.H., Goletti, D., Gilman, R., Lyadova, I.V., Scriba, T.J., Kallas, E.G., Murali-Krishna, K., Sette, A., Lindestam Arlehamn, C.S. 2015. A side-by-side comparison of T cell reactivity to fifty-nine Mycobacterium tuberculosis antigens in diverse populations from five continents. Tuberculosis (Edinb). 95, 713-21. PubMed link

Nayak, K., Jing, L., Russell, R.M., Davies, D.H., Hermanson, G., Molina, D.M., Liang, X., Sherman, D.R., Kwok, W.W., Yang, J., Kenneth, J., Ahamed, S.F., Chandele, A., Murali-Krishna, K., Koelle, D.M. 2015. Identification of novel Mycobacterium tuberculosis CD4 T-cell antigens via high throughput proteome screening. Tuberculosis (Edinb) 95, 275-87 PubMed link

Wrammert J, Onlamoon N, Akondy RS, Perng GC, Polsrila K, Chandele A, Kwissa M, Pulendran B, Wilson PC, Wittawatmongkol O, Yoksan S, Angkasekwinai N, Pattanapanyasat K, Chokephaibulkit K, Ahmed R. 2012. Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans. J Virol. 86: 2911-2918 PubMed link

Marshall, H.D., Chandele, A., Jung, Y.W., Meng, H., Poholek, A.C., Parish, I.A., Rutishauser, R., Cui, W., Kleinstein, S.H., Craft, J., Kaech, S.M. 2011.Differential expression of Ly6C and T-bet distinguish effector and memory Th1 CD4(+) cell properties during viral infection. Immunity 35, 633-646 PubMed link

Chandele, A., Mukerjee, P., Das, G., Ahmed, R., Chauhan, V.S. 2011. Phenotypic and functional profiling of malaria-induced CD8 and CD4 T cells during blood-stage infection with Plasmodium yoelii. Immunology. 2011 132, 273-286 PubMed link

PubMed links: